You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Cellworks' technology predicted drug resistance in newly diagnosed patients with myelodysplastic syndromes.
The UK developers believe that their device has the potential for multiplex testing at the point of care using solid-state nanopore sensing with DNA probes.
An Australian research group is developing a diagnostic test that uses an engineered toxin to detect an abnormal sugar in the blood of ovarian cancer patients.
Qorvo Biotechnologies and Novel Biomarkers Catalyst Lab are developing prototype cartridge-based HCV cAg assays for confirmatory testing.
A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.
The nucleic acid diagnostic platform they are developing doesn't require expensive optics, and it could be available as a manufacturing prototype in about a year.
Some researchers believe that the use of microfluidics in the analysis of exosomes will help clinicians overcome the problem of heterogeneity in cancer cells.
The POC assay is being developed under a DoD contract to detect pathogens that may pose a threat to national security and public health.
The measures are part of a long-term plan for the National Health Service that will be rolled out across the country to detect 3 out of every 4 cancers at an early stage.
The handheld device uses CMOS technology for multiplexed measurement of disease-linked metabolites and could prove useful for inexpensive POC testing.